World Preview 2018 - Embracing the Patent Cliff

Download World Preview 2018 for an in-depth look at how the patent cliff will reshape the drug industry over the next six years and valuable insights into which companies and products will come out as winners.

With EvaluatePharma's World Preview 2018, our complimentary annual report brings together many of our analyses to provide top level insights, from the world’s financial markets, into the expected performance of the industry between now and 2018.

Selected highlights from World Preview 2018 include:

• Worldwide prescription drug sales forecast to total $885bn in 2018 (CAGR 2011 to 2018: +3.1%)
  

• Over $290bn of sales at risk from patent expirations in 2012-18

• Januvia/Janumet world’s largest selling product in 2018

• Pfizer remains top company by Rx sales in 2011; Novartis leading company in 2018

• Global pharmaceutical R&D spend forecast to grow by 1.5% per year to $149bn in 2018

• Gilead’s hepatitis C polymerase inhibitor, GS-7977, most valuable R&D product

• Anti-coagulants set to record highest growth of major therapy categories to 2018

• Key local market prescription sales growth flat in 2011 (USA, Europe & Japan); Japan best performing market (+3% growth)

• Prescription drug sales forecast to decline by 0.9% in 2012 due to large number of patent expiries and decline in value of euro

• Teva continues to lead generic drug market in 2011 but Novartis is catching up

Based on EvaluatePharma’s coverage of the world’s leading 3,500 pharmaceutical and biotech companies, the World Preview 2018 highlights forecast trends in worldwide prescription drug sales, patent risk, global brand sales, R&D spend, market performance by therapy area.

Plus a review of 2011 performance, including a new geographical analysis looking at the performance of the US, Europe and Japan pharmaceutical markets in 2011.